WHO I级颅内脑膜瘤术前栓塞与未栓塞比较:回顾性匹配队列研究
该回顾性匹配队列研究纳入2008至2016年在本机构接受WHO I级颅内脑膜瘤切除的患者,经倾向评分匹配生成栓塞组与未栓塞组各52例。结果显示术前栓塞未改善手术结局,但栓塞组末次随访mRS评分较术前改善的比例高于未栓塞组(50.0% vs 28.8%,p=0.03)。
要点
- 栓塞组与未栓塞组各52例,年龄、肿瘤侧别、位置、直径、静脉窦侵犯及动脉包绕等变量均衡。
- 两组术中估计失血量、Simpson IV级切除、围手术期并发症、永久性新发神经功能缺损及末次随访良好mRS评分均无显著差异。
- 栓塞组末次随访mRS评分较术前改善的比例高于未栓塞组(50.0% vs 28.8%,p=0.03)。
核心结论
- 控制患者年龄、肿瘤大小、侧别、位置、侵犯主要硬脑膜窦及包绕颈内动脉或大脑中动脉后,旨在减少肿瘤血供的术前脑膜瘤栓塞未改善WHO I级颅内脑膜瘤患者的手术结局,但较未栓塞患者有更大机会获得临床改善。
研究设计与样本
- 回顾性匹配队列研究,复习2008至2016年在本机构接受WHO I级颅内脑膜瘤切除的所有患者病例。
- 采用倾向评分匹配生成栓塞组和未栓塞组各52例,并进行临床和影像学结局的回顾性复习。
主要发现
- 栓塞组52例(平均随访34.8±31.5个月)与未栓塞组52例(平均随访32.8±28.7个月;p=0.63)比较。
- 控制的变量包括患者年龄(p=0.82)、肿瘤侧别(p>0.99)、肿瘤位置(p>0.99)、肿瘤直径(p=0.07)、肿瘤侵犯主要硬脑膜窦(p>0.99)及肿瘤包绕颈内动脉或大脑中动脉(p>0.99)。
- 栓塞组与未栓塞组术中估计失血量分别为660.4±637.1 ml与509.2±422.0 ml(p=0.17)。
- 栓塞组与未栓塞组Simpson IV级切除分别为32.7%与25.0%(p=0.39),围手术期操作并发症分别为26.9%与19.2%(p=0.35),永久性新发神经功能缺损分别为5.8%与7.7%(p=0.70),末次随访良好mRS评分(0-2分)分别为96.0%与92.3%(p=0.43)。
- 末次随访mRS评分与术前mRS评分比较,栓塞组较未栓塞组更可能有mRS评分改善(50.0% vs 28.8%;p=0.03)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The controversy continues over the clinical utility of preoperative embolization for reducing tumor vascularity of intracranial meningiomas prior to resection. Previous studies comparing embolization and nonembolization patients have not controlled for detailed tumor parameters before assessing outcomes. METHODS: The authors reviewed the cases of all patients who underwent resection of a WHO grade I intracranial meningioma at their institution from 2008 to 2016. Propensity score matching was used to generate embolization and nonembolization cohorts of 52 patients each, and a retrospective review of clinical and radiological outcomes was performed. RESULTS: In total, 52 consecutive patients who underwent embolization (mean follow-up 34.8 ± 31.5 months) were compared to 52 patients who did not undergo embolization (mean follow-up 32.8 ± 28.7 months; p = 0.63). Variables controlled for included patient age (p = 0.82), tumor laterality (p > 0.99), tumor location (p > 0.99), tumor diameter (p = 0.07), tumor invasion into a major dural sinus (p > 0.99), and tumor encasement around the internal carotid artery or middle cerebral artery (p > 0.99). The embolization and nonembolization cohorts did not differ in terms of estimated blood loss during surgery (660.4 ± 637.1 ml vs 509.2 ± 422.0 ml; p = 0.17), Simpson grade IV resection (32.7% vs 25.0%; p = 0.39), perioperative procedural complications (26.9% vs 19.2%; p = 0.35), development of permanent new neurological deficits (5.8% vs 7.7%; p = 0.70), or favorable modified Rankin Scale (mRS) score (a score of 0-2) at last follow-up (96.0% vs 92.3%; p = 0.43), respectively. When comparing the final mRS score to the preoperative mRS score, patients in the embolization group were more likely than patients in the nonembolization group to have an improvement in mRS score (50.0% vs 28.8%; p = 0.03). CONCLUSIONS: After controlling for patient age, tumor size, tumor laterality, tumor location, tumor invasion into a major dural sinus, and tumor encasement of the internal carotid artery or middle cerebral artery, preoperative meningioma embolization intended to decrease tumor vascularity did not improve the surgical outcomes of patients with WHO grade I intracranial meningiomas, but it did lead to a greater chance of clinical improvement compared to patients not treated with embolization.
引用
- Przybylowski CJ, Zhao X, Baranoski JF, et al. Preoperative embolization versus no embolization for WHO grade I intracranial meningioma: a retrospective matched cohort study. J Neurosurg. 2020. PMID: 32217797. doi:10.3171/2020.1.JNS19788
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。